Insilico Medicine has announced the discovery of novel pan-KRAS inhibitors through its AI-powered generative platform Chemistry42. Combining structure-based drug design and scaffold hopping, the company developed new chemotypes that effectively target multiple KRAS mutations implicated in cancer. These inhibitors demonstrate potency in the upper nanomolar range, overcoming longstanding challenges in targeting the historically “undruggable” KRAS oncogene. The advancement represents a significant AI-driven milestone in oncology drug development.